newsfilter
← Latest News
GlobeNewswire·

SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Initiated a Phase 1 study of SCY-770, a first-in-class, potent and direct AMPK activator for treatment of ADPKD; topline data are expected in Q3 2026 and are anticipated to inform dose selection for the planned Phase 2